66 related articles for article (PubMed ID: 11804272)
1. Strategies to find new genes involved in drug metabolism.
Sheffield LJ
Curr Opin Mol Ther; 2001 Dec; 3(6):579-84. PubMed ID: 11804272
[TBL] [Abstract][Full Text] [Related]
2. Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity.
Hosking LK; Boyd PR; Xu CF; Nissum M; Cantone K; Purvis IJ; Khakhar R; Barnes MR; Liberwirth U; Hagen-Mann K; Ehm MG; Riley JH
Pharmacogenomics J; 2002; 2(3):165-75. PubMed ID: 12082588
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.
Ingelman-Sundberg M
Pharmacogenomics J; 2005; 5(1):6-13. PubMed ID: 15492763
[TBL] [Abstract][Full Text] [Related]
4. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics in Alzheimer's disease.
Cacabelos R
Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors.
Gomes L; Lemos MC; Paiva I; Ribeiro C; Carvalheiro M; Regateiro FJ
Acta Med Port; 2005; 18(5):339-43. PubMed ID: 16611538
[TBL] [Abstract][Full Text] [Related]
7. Multipoint linkage-disequilibrium mapping narrows location interval and identifies mutation heterogeneity.
Morris AP; Whittaker JC; Xu CF; Hosking LK; Balding DJ
Proc Natl Acad Sci U S A; 2003 Nov; 100(23):13442-6. PubMed ID: 14597696
[TBL] [Abstract][Full Text] [Related]
8. The optimal measure of linkage disequilibrium reduces error in association mapping of affection status.
Maniatis N; Morton NE; Gibson J; Xu CF; Hosking LK; Collins A
Hum Mol Genet; 2005 Jan; 14(1):145-53. PubMed ID: 15548543
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
10. Association studies under general disease models.
Nielsen DM; Weir BS
Theor Popul Biol; 2001 Nov; 60(3):253-63. PubMed ID: 11855959
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Schaeffeler E; Schwab M; Eichelbaum M; Zanger UM
Hum Mutat; 2003 Dec; 22(6):476-85. PubMed ID: 14635107
[TBL] [Abstract][Full Text] [Related]
12. Effects of single SNPs, haplotypes, and whole-genome LD maps on accuracy of association mapping.
Maniatis N; Collins A; Morton NE
Genet Epidemiol; 2007 Apr; 31(3):179-88. PubMed ID: 17285621
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
14. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
[TBL] [Abstract][Full Text] [Related]
15. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer.
Lemos MC; Carrilho F; Rodrigues F; Coutinho E; Gomes L; Carvalheiro M; Regateiro FJ
Clin Endocrinol (Oxf); 2007 Aug; 67(2):180-3. PubMed ID: 17547692
[TBL] [Abstract][Full Text] [Related]
17. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
Buzková H; Pechandová K; Slanar O; Perlík F
Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
[TBL] [Abstract][Full Text] [Related]
19. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
Gibbs JP; Hyland R; Youdim K
Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure.
Sistonen J; Sajantila A; Lao O; Corander J; Barbujani G; Fuselli S
Pharmacogenet Genomics; 2007 Feb; 17(2):93-101. PubMed ID: 17301689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
